Powerful hardware services and software libraries are vital tools for quickly and affordably designing, testing, and executing quantum algorithms. A robust large-scale study of how the performance of these platforms scales with the number of qubits is key to providing quantum solutions to challenging industry problems. Such an evaluation is difficult owing to the availability and price of physical quantum processing units. This work benchmarks the runtime and accuracy for a representative sample of specialized high-performance simulated and physical quantum processing units. Results show the QMware cloud computing service can reduce the runtime for executing a quantum circuit by up to 78% compared to the next fastest option for algorithms with fewer than 27 qubits. The AWS SV1 simulator offers a runtime advantage for larger circuits, up to the maximum 34 qubits available with SV1. Beyond this limit, QMware provides the ability to execute circuits as large as 40 qubits. Physical quantum devices, such as Rigetti's Aspen-M2, can provide an exponential runtime advantage for circuits with more than 30. However, the high financial cost of physical quantum processing units presents a serious barrier to practical use. Moreover, of the four quantum devices tested, only IonQ's Harmony achieves high fidelity with more than four qubits. This study paves the way to understanding the optimal combination of available software and hardware for executing practical quantum algorithms.

Cancer is one of the leading causes of death worldwide. It is caused by a variety of genetic mutations, which makes every instance of the disease unique. Since chemotherapy can have extremely severe side effects, each patient requires a personalized treatment plan. Finding the dosages that maximize the beneficial effects of the drugs and minimize their adverse side effects is vital. Deep neural networks automate and improve drug selection. However, they require a lot of data to be trained on. Therefore, there is a need for machine-learning approaches that require less data. Hybrid quantum neural networks were shown to provide a potential advantage in problems where training data availability is limited. We propose a novel hybrid quantum neural network for drug response prediction, based on a combination of convolutional, graph convolutional, and deep quantum neural layers of 8 qubits with 363 layers. We test our model on the reduced Genomics of Drug Sensitivity in Cancer dataset and show that the hybrid quantum model outperforms its classical analog by 15% in predicting IC50 drug effectiveness values. The proposed hybrid quantum machine learning model is a step towards deep quantum data-efficient algorithms with thousands of quantum gates for solving problems in personalized medicine, where data collection is a challenge.